What is new in melanoma after European Cancer Congress 2017?

Abstract

Melanoma ManagementVol. 4, No. 2 CommentaryWhat is new in melanoma after European Cancer Congress 2017?Piotr RutkowskiPiotr Rutkowski*Author for correspondence: E-mail Address: piotr.rutkowski@coi.pl Department of Soft Tissue/Bone Sarcoma & Melanoma, Maria Sklodowska-Curie Institute – Oncology Center, Roentgena 5, 02–781 Warsaw, PolandSearch for more papers by this authorPublished Online:15 May 2017https://doi.org/10.2217/mmt-2017-0004AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: adjuvantanti-CTLA-4anti-PD-1BRAF inhibitorimmunotherapyMEK inhibitormelanomametastasesneoadjuvantReferences1 Autier P, Koechlin A, Boniol M. Prediction of numbers of melanoma deaths by 2050. Presented at: 2017 European Cancer Conference. Amsterdam, The Netherlands, 27–30 January 2017.Crossref, Google Scholar2 Rutkowski P. Introduction to the special issue of European Journal of Surgical Oncology: new roads in melanoma management. Eur. J. Surg. Oncol. 43(3), 513–516 (2017).Crossref, Medline, CAS, Google Scholar3 Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – update 2016. Eur. J. Cancer 63, 201–217 (2016).Crossref, Medline, Google Scholar4 NCCN Guidelines. Melanoma. Version 1. www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdfGoogle Scholar5 Ugurel S, Roehmel J, Ascierto PA et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies. Eur. J. Cancer 53, 125–134 (2016).Crossref, Medline, Google Scholar6 Haanen J, Blank C, Van Thienen H et al. Downsizing of locally advanced stage III (bulky) BRAF V600E/K melanoma with combination targeted therapy to achieve R0 resection. Presented at: 2017 European Cancer Conference. Amsterdam, The Netherlands, 27–30 January 2017.Crossref, Google Scholar7 Long G. Neoadjuvant therapy in bulky stage III melanoma: are we there yet? Presented at: 2017 European Cancer Conference. Amsterdam, The Netherlands, 27–30 January 2017.Google Scholar8 Amaria R. Treatment with neoadjuvant and adjuvant BRAF and MEK inhibitors is associated with improved relapse-free survival over standard-of-care therapy in patients with high risk resectable BRAF-mutant melanoma. Presented at: 2017 European Cancer Conference. Amsterdam, The Netherlands, 27–30 January 2017.Google Scholar9 Blank CU, Van Akkooi A, Rozeman EA et al. (Neo-)adjuvant ipilimumab + nivolumab (Ipi + Nivo) in palpable stage 3 melanoma. Initial data from the OpACIN trial. Ann. Oncol. 27(6), 1–36 (2016).Medline, Google Scholar10 Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375(19), 1845–1855 (2016).Crossref, Medline, CAS, Google Scholar11 Coens C, Suciu S, Chiarion-Sileni V et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, Phase III trial. Lancet Oncol. 18(3), 393–403 (2017).Crossref, Medline, CAS, Google Scholar12 Kim H, Comey S. Two year overall survival rate of all advanced melanoma patients treated with ipilimumab in Australia 2013–2014. Presented at: 2017 European Cancer Conference. Amsterdam, The Netherlands, 27–30 January 2017.Crossref, Google Scholar13 Ascierto P, Bastholt L, Mohr P et al. EURO-VOYAGE: effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL). Presented at: 2017 European Cancer Conference. Amsterdam, The Netherlands, 27–30 January 2017.Crossref, Google Scholar14 Long GV, Blank C, Ribas A et al. Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006. Presented at: 2017 European Cancer Conference. Amsterdam, The Netherlands, 27–30 January 2017.Crossref, Google Scholar15 Butler M, Hamid O, Ribas A et al. Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies. Presented at: 2017 European Cancer Conference. Amsterdam, The Netherlands, 27–30 January 2017.Crossref, Google Scholar16 D'Angelo SP, Larkin J, Sosman JA et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J. Clin. Oncol. 35(2), 226–235 (2016).Crossref, Medline, Google Scholar17 Long GV, Robert C, Arance A et al. Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006. Presented at: 2017 European Cancer Conference. Amsterdam, The Netherlands, 27–30 January 2017.Crossref, Google ScholarFiguresReferencesRelatedDetails Vol. 4, No. 2 Follow us on social media for the latest updates Metrics Downloaded 26 times History Published online 15 May 2017 Published in print May 2017 Information© Future Medicine LtdKeywordsadjuvantanti-CTLA-4anti-PD-1BRAF inhibitorimmunotherapyMEK inhibitormelanomametastasesneoadjuvantFinancial & competing interests disclosureP Rutkowski served as a member of Advisory Board for Novartis, GSK, MSD, Roche, BMS, Amgen and Bayer. He had received honoraria for lectures from Novartis, Pfizer, BMS, MSD, Roche. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download